Paligenosis defines a tightly controlled program through which terminally differentiated cells re‑enter the cell cycle and ...
Findings of a new study introduce new drug targets to selectively inhibit a key event in tumor cell progression. The study provides further insight into the control of mTORC1 activation, and ...
A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...
It has long been known that the protein TOR – Target of Rapamycin – controls cell growth and is involved in the development of diseases such as cancer and diabetes. Through a collaborative effort ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results